Emese Zsiros, MD, PhD, on Platinum-Resistant Recurrent Ovarian Cancer: Pembrolizumab Plus Weekly Paclitaxel

Emese Zsiros, MD, PhD, of Roswell Park Comprehensive Cancer Center, reviews results from the randomized, double-blind, phase III ENGOT-ov65/KEYNOTE-B96 trial. According to the study investigators, “Pembrolizumab in combination with weekly paclitaxel with or without bevacizumab demonstrated statistically significant and clinically meaningful improvement in progression-free survival regardless of PD-L1 status and in overall survival in participants with PD-L1–expressing tumor (CPS ≥ 1).... This is the first phase III study to report a statistically significant improvement in overall survival with an immune checkpoint inhibitor–based regimen in ovarian cancer.” (Abstract LBA3)